GSTP1 and NQO1 are then needed to detoxify these ROS species and MNPC, through inhibition of both enzymes attacks this “Achilles heel.” Conceivably, the development of MNPC as a novel anticancer agent will provide an unprecedented strategy for GBM cancer therapy. Here, NQO1 is linked to glioblastoma.